secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001178913-26-002267
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion submits Phase 2/3 trial application to Germany's BfArM for SIL204 in KRAS-driven pancreatic cancer
--------------------------------------------------------------------------------

- Silexion submitted CTA to Germany’s BfArM for Phase 2/3 trial of SIL204 in KRAS-driven locally advanced pancreatic cancer.
- Germany will serve as EU Reference Member State; trial initiation remains on track for Q2 2026.
- Submission supported by completed two-species toxicology studies confirming no systemic organ toxicity.
- Planned trial will evaluate SIL204 in combination with standard chemotherapy using dual-route administration.
- Pancreatic cancer has <13% five-year survival; KRAS mutations present in about 90% of cases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002267/0001178913-26-002267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002267/zk2635144.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer